Sensitivity and specificity of P53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma

Urologia Internationalis

Volumn 79, Issue 4, 2007, Pages 321-327

  Salinas Sánchez, Antonio S ^a,b   Atienzar Tobarra, Manuel ^a   Lorenzo Romero, Juan G ^a   Sánchez Sánchez, Francisco ^a   Giménez Bachs, José M ^a   Donate Moreno, María J ^a   Pastor Navarro, Héctor ^a   Hernández Millán, Ibrahim ^a   Segura Martín, Miguel ^a   Escribano Martínez, Julio ^a  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b NONE   (Spain)

Author keywords

Bladder cancer; Immunohistochemistry; Mutations; P53; Prognostic value of p53 gene alterations; Single strand conformational polymorphism

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GOLD STANDARD; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SINGLE STRAND CONFORMATION POLYMORPHISM;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CARCINOMA, TRANSITIONAL CELL; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROBABILITY; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 36248943524     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109717     Document Type: Article

References (27)

1. Cordon-Cardo C: Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-560.
2. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutation in the p53 suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
3. Berns A: Is p53 the only real tumor suppressor gene? Current Biol 1994;4:115-119.
4. Álvarez Kindelán J, López-Beltrán A, Requena Tapia MJ: Biología molecular en el cáncer vesical. Actas Urol Esp 2000;24:604-625.
5. Lorenzo Romero JG, Salinas Sánchez AS, Giménez Bachs JM, et al: Prognostic implications of p53 gene mutation in bladder tumors. J Urol 2003;169:492-499.
6. Cordon Cardo C, Reuter VE: Alterations of suppressor genes in bladder cancer. Semin Diagn Pathol 1997;14:123-132.
7. Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1262.
8. Bergh J, Norberg T, Sjogren S, et al: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-1034.
9. Bernardini S, Adessi GL, Billerey C, et al: Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol 1999;162:1496-1501.
10. Vet JAM, Bringuier PP, Schaafsma HE, et al: Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest 1995;73:837-843.
11. Ito K, Sasano H, Matsunaga G, et al: Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997;183:318-324.
12. Goudopoulou A, Saetta A, Korkolopoulou P, et al: p53 mutations detection in urinary bladder cancer in the Greek population: application of the NIRCA assay. J Exp Clin Cancer Res 2003;22:99-105.
13. Weintraub M, Khaled HM, Zekri AR, et al: P53 mutations in Egyptian bladder cancer. Int J Oncol 1995;7:1269-1274.
14. Llopis J, Alcaraz A, Ribal MJ, et al: P53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol 2000;37:644-653.
15. Erill N, Colomer A, Verdu M, et al: Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol 2004;13:217-223.
16. Nakopoulou L, Constantinides C, Papandropoulos J, et al: Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology 1995;46:334-340.
17. Esrig D, Spruck CH 3rd, Nichols PW, et al: p53 nuclear protein accumulation correlates with mutation in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-1397.
18. Clausen OP, Lothe RA, Borresen-Dale AL, et al: Association of p53 accumulation with TP53 mutations, loss of heterozygosity at 17p13, and DNA ploidy status in 273 colorectal carcinomas. Diagn Mol Pathol 1998;7:215-223.
19. Calistri D, Barzanti F, Dal Susino M, et al: Correlation between p53 gene mutations and p53 protein accumulation evaluated by different methodologies. J Biol Regul Homeost Agents 2000;14:120-127.
20. Uchida T, Wada C, Ishida H, et al: p53 mutations and prognosis in bladder tumors. J Urol 1995;153:1097-1104.
21. Hayashi K: PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. PCR Methods Appl 1991;1:34-38.
22. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 1991;351:453-456.
23. Haupt Y, Maya R, Kazaz A, et al: Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
24. Fromentel C, Soussi T: The p53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992;4:1-15.
25. Yamamoto S, Tada M, Lee CC, Masuda C, Wanibuchi H, Yoshimura R, Wada S, Yamamoto K, Kishimoto T, Fukushima S: p53 status in multiple human cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry. Jpn J Cancer Res 2000;91:181-189.
26. Van der Poel HG, Hessels K, Van Leenders GJ, Bussemakers MJ, Schalken JA, Witjes LA, Debruyne MJ: Multifocal transitional cell cancer and p53 mutation analysis. J Urol 1998;160:124-125.
27. Prescott J, Patel H, Tillman S, et al: Cleavage of double-stranded copy RNA by RNase 1 and RNase T1 provides a robust means to detect p53 gene mutations in clinical specimens. Electrophoresis 1999;20:1149-1161.